GSK drops despite 14% specialty surge
GSK (LSE:GSK) Reports Q1 sales of £7.6bn, with Specialty Medicines leading the charge at £3.2bn, up 14% Year-on-year. The company reiterates its full-year 2026 guidance at constant exchange rates, a signal of confidence in the pipeline and commercial execution. Shares nonetheless fall 6.66% To 1893.0p, with investors apparently unwilling to chase a stock that has run hard into results.
AstraZeneca holds guidance as Q1 revenue climbs 8%
AstraZeneca (LSE:AZN) Posts Q1 Total Revenue of $15,288m, an 8% Increase at constant exchange rates, and reconfirms FY 2026 guidance of mid-to-high single-digit Total Revenue growth alongside low double-digit Core EPS growth. The guidance reaffirmation mirrors the tone set by peers across the session, yet the stock sheds 2.81% To 13510.0p As macro headwinds weigh on large-cap healthcare broadly.
FRP forensic report on SkinBioTherapeutics days away
SkinBioTherapeutics (LSE:SBTX) Tells shareholders that FRP Advisory is finalising its forensic investigation and will deliver the report to the board within days. The company offers no further detail on the scope or likely findings of the review. Shares fall 4.88% To 9.75p As investors sit with the uncertainty ahead of the report's arrival.
Solvonis doubles down on Phase 3 CNS push
Solvonis Therapeutics (LSE:SVNS) Sets out its priorities following a repositioning as a focused CNS biopharmaceutical business, confirming it will direct resources toward completing Phase 3 trials for lead asset SVN-001. The company closes 2025 with cash and equivalents of £1.720m, a thin runway that underscores the urgency of the Phase 3 timeline. Shares slip 3.53% To 0.2595p.
Ondine raises £5m to advance NDA and FDA
Ondine Biomedical (LSE:OBI) Completes a £5m Placing, issuing 41.67m New shares at 12p Each to fund NDA preparation, GMP commercial-scale manufacturing, and ongoing FDA engagement. The raise extends the company's cash runway to early Q4 2026. Shares trade at 11.652p, down 6.78% On the day, reflecting the dilutive effect of the placing price relative to recent trading levels.
